Experts Available to Discuss Implications of New FDA-Approved Weight Loss Drug, ContraveThe Obesity Society Calls FDA Approval of Contrave a Step to Improve Health, Weight of Nation
“As the number of Americans affected by severe obesity continues to rise, equipping our nation's doctors with proven and effective tools to treat patients for this disease is increasingly important. Today's Food and Drug Administration (FDA) announcement that Contrave™ has been approved for long-term treatment of obesity is an important step toward this goal and can help improve the health and weight of our nation.” – Dr. Lee Kaplan, The Obesity Society Clinical Committee Chair
The following experts in obesity treatment from The Obesity Society are available for interviews:
Lee Kaplan, MD, PhD, Fellow of The Obesity Society (FTOS)Chair, Clinical Committee, The Obesity SocietyDirector, Obesity, Metabolism and Nutrition Institute Massachusetts General Hospital
Lee M. Kaplan, MD, PhD, FTOS, is chair of the clinical committee at The Obesity Society, among other leadership roles. He is currently director of the Obesity, Metabolism and Nutrition Institute and founding director of the Weight Center at the Massachusetts General Hospital (MGH), and associate professor of medicine at Harvard Medical School (HMS). He is director of the Obesity Medicine and Nutrition subspecialty fellowship program at MGH and of the Blackburn Course in Obesity Medicine at HMS, and Chairman Emeritus of the Campaign to End Obesity. He graduated from Harvard University, received his MD and PhD in molecular biology from the Albert Einstein College of Medicine and completed his residency in Internal Medicine and fellowships in gastroenterology and genetics at MGH.
The author of more than 150 medical and scientific papers, Dr. Kaplan’s research is focused on the gastrointestinal regulation of energy balance and metabolic function, including the mechanisms of action of bariatric surgery and other GI interventions. He currently serves on the editorial boards of several scientific and medical journals and the external advisory boards of several NIH-sponsored research programs.
Adam Gilden Tsai, MD, MSCE, FACPChair, Public Affairs Committee, The Obesity SocietyPracticing Internal Medicine Physician at Kaiser Permanente of Colorado, Departments of Internal Medicine and Metabolic-Surgical Weight Management
Adam Gilden Tsai, MD, MSCE, FACP, is the chair of the Public Affairs Committee at The Obesity Society and an internal medicine physician in Denver, Colorado. He practices internal medicine and obesity medicine at Kaiser Permanente of Colorado. Dr. Tsai is also Associate Professor of Medicine (adjunct) at the University of Colorado, where he worked for 5 years before moving to Kaiser Permanente. He has published more than 50 peer-reviewed papers in clinical obesity research, including publications in the New England Journal of Medicine, Journal of the American Medical Association, and Annals of Internal Medicine. His primary research interests include obesity treatment in primary care settings as well as economics of obesity treatment. He is board certified in internal medicine and obesity medicine.
About The Obesity SocietyThe Obesity Society (TOS) is the leading professional society dedicated to better understanding, preventing and treating obesity. Through research, education and advocacy, TOS is committed to improving the lives of those affected by the disease. For more information visit: www.Obesity.org.
RSS